SEC Form 4
Alnylam Pharmaceuticals, Inc. (ALNY) insider trading
In the 12 months to Oct 26, 2026, 5 ALNY insiders reported open-market sales of $24.1M across 11 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $24.1M
- 11 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 11 of 11
- All $24.1M sold was pre-arranged
Who traded ALNY, and when
- Sale
- Sale, pre-arranged (10b5-1)
ALNY daily close from Oct 27, 2025 to Oct 26, 2026, between $205.48 and $481.59, last $226.58. 11 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Yvonne Greenstreet, Chief Executive Officer: sold $11.6M across 1 filing, first filed Nov 14, 2025, last Nov 14, 2025. Kevin Joseph Fitzgerald, CSO & EVP, Head of Research: sold $7.8M across 5 filings, first filed Nov 19, 2025, last Mar 6, 2026. Pushkal Garg, EVP Chief R&D: sold $2.9M across 3 filings, first filed Mar 2, 2026, last Mar 6, 2026. David E. I. Pyott, Director: sold $1.1M across 1 filing, first filed Jun 3, 2026, last Jun 3, 2026. Melissa McLaughlin, Chief Human Resources Officer: sold $755.3K across 1 filing, first filed Apr 7, 2026, last Apr 7, 2026.
Largest mark · tap a row for others
Yvonne Greenstreet · Chief Executive Officer
Sale $11,613,003
25,650 shares at $452.75 avg
Filed Nov 14, 2025 · traded Nov 12
Pre-arranged (10b5-1) · close on filing date $449.16
Yvonne Greenstreet · Chief Executive Officer
Chief Executive Officer
$11.6M soldKevin Joseph Fitzgerald · CSO & EVP, Head of Research
CSO & EVP, Head of Research
$7.8M soldPushkal Garg · EVP Chief R&D
EVP Chief R&D
$2.9M soldDavid E. I. Pyott · Director
Director
$1.1M soldMelissa McLaughlin · Chief Human Resources Officer
Chief Human Resources Officer
$755.3K soldOpen-market trades
11 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Yvonne Greenstreet | Chief Executive Officer | $11.6M | — | 1 | 100% of sales | |
| Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | $7.8M | — | 5 | 100% of sales | |
| Pushkal Garg | EVP Chief R&D | $2.9M | — | 3 | 100% of sales | |
| David E. I. Pyott | Director | $1.1M | — | 1 | 100% of sales | |
| Melissa McLaughlin | Chief Human Resources Officer | $755.3K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | David E. I. Pyott Director | SalePre-arranged (10b5-1) | 3,830 | $299.18 | $1.1M | 4,491 | |
traded | Melissa McLaughlin Chief Human Resources Officer | SalePre-arranged (10b5-1) | 2,286 | $330.42 | $755.3K | 9,443 | |
traded | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | SalePre-arranged (10b5-1) | 658 | $323.98 | $213.2K | 20,722 | |
traded | Pushkal Garg EVP Chief R&D | SalePre-arranged (10b5-1) | 2,404 | $323.96 | $778.8K | 19,193 | |
traded | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | SalePre-arranged (10b5-1) | 1,652 | $319.73 | $528.2K | 23,223 | |
traded | Pushkal Garg EVP Chief R&D | SalePre-arranged (10b5-1) | 1,775 | $319.74 | $567.5K | 23,406 | |
traded | Pushkal Garg EVP Chief R&D | SalePre-arranged (10b5-1) | 4,627 | $331.34 | $1.5M | 23,211 | |
traded | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | SalePre-arranged (10b5-1) | 2,041 | $331.96 | $677.5K | 21,264 | |
traded | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | SalePre-arranged (10b5-1) | 2,290 | $370.33 | $848.1K | 22,151 | |
traded | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | SalePre-arranged (10b5-1) | 12,128 | $452.18 | $5.5M | 24,267 | |
traded | Yvonne Greenstreet Chief Executive Officer | SalePre-arranged (10b5-1) | 25,650 | $452.75 | $11.6M | 65,865 |
GET /stocks/filings/vX/form-4?tickers=ALNY&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ALNY"
],
"issuer_cik": "0001178670",
"owner_cik": "0001051578",
"accession_number": "0001178670-26-000048",
"form_type": "4",
"filing_date": "2026-06-03",
"period_of_report": "2026-06-01",
"issuer_name": "ALNYLAM PHARMACEUTICALS, INC.",
"issuer_trading_symbol": "ALNY",
"owner_name": "PYOTT DAVID E I",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1175,
"transaction_price_per_share": 298.91,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 3316,
"transaction_value": 351219.25000000006,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026."
},
{
"id": "F3",
"description": "The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."
}
]
},
{
"tickers": [
"ALNY"
],
"issuer_cik": "0001178670",
"owner_cik": "0001051578",
"accession_number": "0001178670-26-000048",
"form_type": "4",
"filing_date": "2026-06-03",
"period_of_report": "2026-06-01",
"issuer_name": "ALNYLAM PHARMACEUTICALS, INC.",
"issuer_trading_symbol": "ALNY",
"owner_name": "PYOTT DAVID E I",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 17,
"transaction_price_per_share": 302.65,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1582,
"transaction_value": 5145.049999999999,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 252 records
- Option exercises14 records
- Tax withholding1 record
- Tax withholding (sold to cover)210 records
- Grants and awards27 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Alnylam Pharmaceuticals, Inc.'s CEO sold stock?
Yes. Yvonne Greenstreet (CEO) sold 25,650 shares ($11.6M) in Nov 2025, all under a pre-arranged 10b5-1 plan.
How current is ALNY’s insider data?
These are ALNY Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ALNY insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ALNY every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.